Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study

Background: Pirfenidone, an antifibrotic medication approved for the treatment of idiopathic pulmonary fibrosis (IPF), often requires dose reduction owing to adverse events. In this study, we evaluated if pirfenidone’s reduced dose has any impact on clinical outcomes in patients with IPF. Methods: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jieun, Chung, Man Pyo, Park, Moo Suk, Oh, In Jae, Lee, Heung Bum, Kim, Young Whan, Park, Jong Sun, Uh, Soo Taek, Kim, Yun Seong, Jegal, Yangjin, Song, Jin Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871582/
https://www.ncbi.nlm.nih.gov/pubmed/36703754
http://dx.doi.org/10.3389/fphar.2022.1025947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871582/
https://www.ncbi.nlm.nih.gov/pubmed/36703754
http://dx.doi.org/10.3389/fphar.2022.1025947

Ejemplares similares